Phase III Clinical Study of JTE-052A - Randomized Controlled and Long-term Extension Study in Patients with Atopic Dermatitis -

Trial Profile

Phase III Clinical Study of JTE-052A - Randomized Controlled and Long-term Extension Study in Patients with Atopic Dermatitis -

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Delgocitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Japan Tobacco
  • Most Recent Events

    • 12 Jan 2018 According to a Japan Tobacco media release, data from this study with other ongoing phase 3 studies will be used to submit a marketing application for JTE-052 ointment in Japan.
    • 12 Jan 2018 According to a Japan Tobacco media release, Primary endpoint (change of the mEASI score from baseline) has been met.
    • 05 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top